FDA Approved: COMBIVENT RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Combivent Respimat (ipratropium bromide and albuterol) by Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Combivent Respimat (ipratropium bromide and albuterol sulfate)

Snippet

SUPPL AP for COMBIVENT RESPIMAT (IPRATROPIUM BROMIDE AND ALBUTEROL)